Is Your Clinical Trial Representing All Populations?

In 2020, 75% of clinical trial participants were white—a significant overrepresentation compared to the diversity of the U.S. population. Without a more balanced participant pool, clinical trials risk skewing results and failing to address the needs of all populations.

Why Population Diversity is Critical for Clinical Trials

Incorporating external patient demographics, geospatial data, and other population information can:

Ensure accurate trial results by reflecting the diversity of those who will use the treatment
Increase patient confidence in the drug’s effectiveness and safety
Promote fairness & equality by representing underrepresented communities
Support FDA & NIH compliance by meeting diversity mandates

How It Works

🔹 Predict patient participation using predictive modeling and targeted recruitment
🔹 Gauge community interest through NLP algorithms that analyze social media and forums
🔹 Ensure equitable representation with diverse patient outreach and data collection

Real-World Impact: Data-Driven Clinical Trial Diversity

In response to underrepresentation, a company paused its trial to recruit more participants of color, addressing the 7% Black representation vs. 13% in the population. This approach ensured more accurate and inclusive results that gained broader patient trust.

Make Your Clinical Trials Truly Inclusive

Incorporating population data isn’t just about compliance—it’s about ensuring that all patients have confidence in new treatments.

📩 Ready to improve the diversity of your clinical trials? Contact us today to learn how data-driven insights can enhance your research.

[Talk to a Data Expert]